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Abstract The phenylephrine-induced complex-1 (PEX1) transcription factor, also known as zinc-
finger protein 260 (Zfp260), is an effector of endothelin-1 and α1-adrenergic signaling in cardiac 
hypertrophy. However, the role of PEX1 in transcriptional regulation of myocardial remodeling 
remains largely unknown. In the present study, we used PEX1 gain- and loss-of-function to examine 
the effects of PEX1 on left ventricular remodeling. Adenoviral constructs expressing PEX1, antisense 
PEX1, or LacZ were delivered by local injection into the anterior wall of the left ventricle in Sprague-
Dawley rats. PEX1 overexpression led to induction of hypertrophic gene program and increased 
fibrosis. In agreement with this, the expression of genes involved in the fibrotic process, such as 
collagens I and III, matrix metalloproteinases (MMPs), fibronectin-1, transforming growth factor beta 
-1 and connective tissue growth factor, were significantly up-regulated following PEX1 
overexpression, whereas silencing of PEX1 significantly inhibited the expression of pro-fibrotic 
genes and increased left ventricular ejection fraction and fractional shortening. In vitro luciferase 
reporter assays showed that PEX1 regulates the expression of MMP-9 by directly binding to its 
promoter. Furthermore, PEX1 gain- and loss-of-function experiments in rat neonatal cardiac 
fibroblasts and myocytes revealed that MMP-9 gene expression was affected by PEX1 
predominantly in fibroblasts. Our results indicate that PEX1 is involved in regulating cardiac fibrosis 
and extracellular matrix turnover, particularly fibroblasts being responsible for the fibrosis-associated 
changes in gene expression. Furthermore, PEX1 activation of the MMP-9 promoter triggers the pro-
fibrotic response directed by PEX1.  
 
Keywords Fibrosis  Hypertrophy  Myocardial remodeling  Signal transduction  Transcription 
factor 
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Introduction 
Left ventricular hypertrophy (LVH) is an adaptive response to pathological conditions, including 
systemic hypertension, myocardial infarction (MI) and valvular heart disease, which increase 
workload on the heart (Chan et al. 2012). Although LVH is initiated as a compensatory mechanism 
to help the myocardium to sustain the mechanical load and ischemic damage, prolongation of this 
process is maladaptive, leading to significant thickening of ventricular wall and subsequent heart 
failure, which is the leading cause of morbidity and mortality worldwide (Braunwald 2013). 
Extracellular matrix (ECM) alterations are fundamental for the post-MI cardiac remodeling 
process, which consists of three overlapping stages: inflammation, proliferative or granulation phase, 
and maturation. At the early stage, there is an acute pro-inflammatory response followed by 
infiltration of the damaged area by neutrophils and macrophages, as well as activation of fibroblasts 
(van Nieuwenhoven and Turner 2013; Shinde and Frangogiannis 2014). Cardiac fibroblasts play a 
major role in ECM maintenance in the adult heart, and increasing evidence indicates that they act 
as sentinel cells that can be activated under cardiac stress and transform phenotypically into 
myofibroblasts (MFs) (Fan et al. 2012; van Nieuwenhoven and Turner 2013; Lindner et al. 2014; 
Shinde and Frangogiannis 2014; Talman and Ruskoaho 2016). Activated fibroblasts migrate to the 
damaged area and contribute to the healing process. During the proliferative phase, the ischemic 
tissue is cleared off dead cells and ECM degradation is promoted by increased presence of matrix 
metalloproteinases (MMPs) to facilitate revascularization (Fan et al. 2012; van Nieuwenhoven and 
Turner 2013; Shinde and Frangogiannis 2014). At the final stage, anti-inflammatory and pro-fibrotic 
signaling [such as interleukin-10 (IL-10) and transforming growth factor beta (TGFβ)] prevails. In 
response to this, MFs synthesize increasing amounts of ECM structural proteins, such as fibronectin 
(FN), and type I and III collagens (Serini et al. 1998; Sun et al. 2000; Shinde and Frangogiannis 
2014). In addition, MFs express contractile proteins, such as α-smooth muscle actin (α-SMA), that 
allow them to contract the scar and enable wound healing (Sun et al. 2000; Frangogiannis 2000; 
Shinde and Frangogiannis 2014). Therefore, the primary goal of ECM remodeling is protective, by 
strengthening the ventricles to sustain a functional myocardium. However, excessive scarring 
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increases tissue rigidity and impairs ventricular function, thereby enhancing heart failure 
progression. 
Regardless of the etiology of cardiac remodeling, it involves activation of a complex network 
of interconnected signaling cascades, which culminate at the nucleus with the activation of a defined 
set of transcription factors (TF). Many of these TFs have an important role in cardiac development 
and are re-employed during pathophysiological stress (Oka et al. 2007). In turn, TFs direct the 
changes in gene expression and re-activation of the fetal gene program, which ultimately leads to 
structural and functional changes in the heart. The phenylephrine-induced complex-1 (PEX1) TF, 
also known as zinc-finger protein 260 (Zfp260), is an effector of endothelin-1 and α1-adrenergic 
signaling (Debrus et al. 2005; Komati et al. 2011). Previous studies have shown that PEX1 physically 
and functionally interacts with GATA4 (Debrus et al. 2005), a master regulator of cardiac 
development and the hypertrophic response in cardiomyocytes (Pikkarainen et al. 2003; Pikkarainen 
et al. 2004; Rysä et al. 2010). Specific cardiomyocyte overexpression of PEX1 in vivo and in vitro 
caused myocyte hypertrophy and induced re-expression of fetal genes associated with the 
hypertrophic response (Komati et al. 2011). However, the role of PEX1 in transcriptional regulation 
of cardiac remodeling, especially within non-myocyte cell populations, remains largely unknown.   
This study was designed to explore the effects of PEX1 gain- and loss-of-function in the adult 
heart as a potential modulator of the cardiac ECM remodeling. Here we show that overexpression 
of PEX1 in the rat left ventricle (LV) induced cardiac fibrosis and up-regulation of fibrosis-associated 
genes as well as re-activation of the fetal gene program. Gain-of-function experiments in vitro 
indicated that the pro-fibrotic effects are largely due to transcriptional changes triggered in 
fibroblasts, and not in cardiomyocytes. Furthermore, promoter binding studies showed that PEX1 
directly binds to the MMP-9 promoter, highlighting the role of PEX1 as modulator of ECM turnover 
during cardiac remodeling.  
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Materials and Methods 
PEX1 gene overexpression and silencing 
Recombinant replication-deficient type 5 adenoviruses containing HA-tagged – coding region for 
PEX1 (Ad5-HA-PEX1) or antisense region directed specifically towards PEX1 (Ad5-AsPEX1) were 
produced as previously reported (Debrus et al. 2005; Komati et al. 2011). The Ad5-LacZ coding β-
galactosidase LacZ was used as adenoviral control. Predesigned small interference RNA (siRNA) 
directed against rat PEX1 (NM_017364) and the AllStars Negative Control siRNA were used for in 
vitro PEX1 silencing experiments. All siRNA constructs and HiPerFect reagent were obtained from 
Qiagen (Hilden, Germany). 
 
Intramyocardial Gene Transfer 
Male 8-week-old Sprague-Dawley rats (250-300 g) from the colony of the Center of Experimental 
Animals at the University of Oulu, Finland, were used. Adenovirus-mediated gene transfer was 
performed as a local intramyocardial injection (1 x 109 pfu in 100 µl total volume) with a Hamilton 
precision syringe directly into the LV free wall as an efficient site-specific method for transgene 
expression without affecting other organs or other areas of the heart (Rysä et al. 2010). After the 
operation, anaesthesia was partially antagonized with atipamezole hydrochloride (Antisedan, 1.5 
mg/kg, intraperitoneal) and rats were hydrated with physiological saline solution (5 ml 
subcutaneous). For postoperative analgesia, buprenorphine hydrochloride (Vetergesic, 0.05–0.2 
mg/kg, subcutaneous) was administered. All animal procedures were approved by the Animal Use 
and Care Committee of the University of Oulu and the Provincial Government of Southern Finland 
Department of Social Affairs and Health and conform to the guidelines from Directive 2010/63/EU of 
the European Parliament on the protection of animals used for scientific purposes. 
 
Acute Myocardial Infarction 
MI was produced by ligation of the left anterior descending (LAD) coronary artery in anaesthetized 
rats (Tenhunen et al. 2006b; Rysä et al. 2010). Rats were anesthetized with ketamine (50 mg/kg, 
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intrapreritoneal) and xylazine//medetomidine (10 mg/kg, intraperitoneal). The adenoviral gene 
transfer was performed before LAD ligation. 
 
Angiotensin II-Induced Hypertension 
In a separate series of experiments, angiotensin II (Ang II, 33.3 µg/kg per hour) was administered 
via subcutaneously implanted osmotic minipumps for 1 week and 2 weeks (Alzet model 2002, 
DURECT Corporation, Cupertino, CA, USA) (Serpi et al. 2011). The minipumps were implanted in 
SD rats under inhaled anesthesia with isoflurane (Baxter International Inc.). Recombinant 
adenovirus was injected after minipump implantation. In this experimental model of hypertension, 
the mean arterial pressure increases within 3 hours and it is sustained throughout 2 weeks (Suo et 
al. 2002). 
 
Echocardiography 
Transthoracic echocardiography was performed using the Vevo2100 high frequency high resolution 
linear array ultrasound system (FujiFilm VisualSonics Inc, Toronto, Canada) and MS-250 transducer 
(13-24MHz, axial resolution 75µm, lateral resolution 165µm) by a trained sonographer blinded to the 
treatments. Rats were anesthetized with ketamine (50 mg/kg, intrapreritoneal) and xylazine (10 
mg/kg, intraperitoneal). Using two-dimensional imaging, a short axis view of the left ventricle at the 
level of the papillary muscles was obtained, and a two dimensionally guided M-mode recording 
through the anterior and posterior walls of the LV were acquired. LV end-systolic and end-diastolic 
dimensions as well as the thickness of the interventricular septum and posterior wall were measured 
from the M-mode tracings. LV fractional shortening (FS) and ejection fraction (EF) were calculated 
from the M-mode LV dimensions using the equations 1 and 2:  
FS(%) = {(LVEDD-LVESD)/LVEDD}×100 (1) 
EF(%) = {(LVEDD)3-(LVESD)3/LVEDD3}×100 (2) 
An average of three measurements of each variable was used. After echocardiographical 
measurements at 3 days, 1 week or 2 weeks, the animals were sacrificed, hearts were excised and 
tissue samples were processed for histological tests and expression characterization. 
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Histology and immunochemistry  
The upper transversal mid-section of the heart was fixed in 10% buffered formalin solution and then 
embedded in paraffin. Five μm thick sections were sliced from the mid-section of the heart at the 
level of the papillary muscles. In order to make the samples fully comparable, samples from different 
animals were obtained in an identical way and from the corresponding sites. The sections were 
deparaffinized in xylene and dehydrated in graded ethanol series. Sections were stained with 
Masson’s trichrome and Picrosirius red (Direct Red 80, Sigma-Aldrich, St. Louis, MO, USA). The 
total fibrotic area of the LV was measured from 5 hotspots in the Masson’s trichrome stained 
sections. Picrosirius red-stained sections were visualized with linear polarized light (Olympus BX51).  
Wheat germ agglutin/5′-fluorescein isothiocyanate (WGA-FITC) was used to quantify 
cardiomyocyte cross sectional area. The cell area was calculated by measuring a total of 10-15 cells 
(from 5 LV fields) per heart using Adobe Image CS5 software. Apoptotic cells were determined by 
terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) method, according 
to the manufacturer’s protocol (ApopTag Red in situ apoptosis detection kit, Chemicon). Primary 
antibodies for Ki-67, von Willebrand factor (vWF), and c-kit were used to label proliferating cells, 
endothelial cells, and cardiac stem cells, respectively.  
The efficiency of PEX1 adenoviral gene transfer was confirmed by specific immunodetection 
of PEX1 with polyclonal anti-PEX1 antibody (Debrus et al. 2005). Immunofluorescent co-staining 
was used to visualize the cell-specificity of adenoviral PEX1 expression. Specific cell markers for 
fibroblasts (prolyl-4-hydroxylase, P4H) and myocytes (α-actinin) were used in combination with anti-
PEX1 antibody. Images were generated using 3DHISTECH Pannoramic 250 FLASH II digital slide 
scanner at the Genome Biology Unit (Research Programs Unit, Faculty of Medicine, University of 
Helsinki, Biocenter Finland) and the Institute of Biotechnology (University of Helsinki). Table 1 in the  
Electronic Supplementary Materials contains the details of all the antibodies utilized. 
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Primary neonatal cell culture 
The cell culture medium components [Dulbecco’s modified Eagle’s medium (DMEM)/F-12, fetal 
bovine serum (FBS) and 100 IU/ml penicillin-streptomycin, bovine serum albumin, 1µM insulin, 
2.8mM sodium pyruvate, 5.64 µg/ml transferrin, 1 nM T3] were all purchased from Sigma-Aldrich 
(St. Louis, MO). Neonatal rat ventricular myocytes (NRVM) and fibroblasts (NRVF) were prepared 
from 2- to 4-days-old Sprague-Dawley rats using the collagenase dissociation method as described 
before (Pikkarainen et al. 2003). The animals were killed by decapitation and the ventricles were 
excised. Differential attachment preplating was used to separate non-myocytes from myocytes. 
NRVM were recovered from the unattached fraction and were seeded (1.5-2 x 105 cells/cm2) in 12-
well plates. The attached fraction is enriched with NRVF, which were passaged twice before seeding 
for the experiment (0.75-1 x 105 cells/cm2 into 12-well plates). The cells were maintained in DMEM/F-
12 supplemented with 10% FBS and 100 IU/ml penicillin-streptomycin. After 24 hours, cells were 
changed to culture serum-free media (CSFM), containing DMEM/F-12 supplemented with 2.5 mg/ml 
bovine serum albumin, 1µM insulin, 2.8mM sodium pyruvate, 5.64 µg/ml transferrin, 1 nM T3, and 
100 IU/ml penicillin-streptomycin.  
NRVM or NRVF were infected 18-24 hours after the initial plating with Ad5-HA-PEX1 or Ad5-
LacZ (MOI 2) for overexpression experiments, and PEX1-siRNA or AllStars Negative Control siRNA 
were used for silencing experiments. The transfection of synthetic siRNAs was achieved by using 
HiPerFect reagent according to the manufacturer instructions. Briefly, on the day of transfection, the 
cells were washed and changed to CSFM. The siRNAs and HiPerFect were diluted in DMEM and 
gently mixed to achieve the final concentration of 5 nM siRNA and of 4 µl HiPerFect/well, and 
incubated at room temperature to allow the formation of siRNA-HiPerFect complexes. Transfection 
silencing complexes or adenoviruses were added to the cells and incubated at 37˚C and 5% CO2. 
The cell culture medium was replaced every 24 hours. The cells were washed twice with ice-cold 
PBS and quickly frozen at -70°C after 24 to 72 hours, accordingly to the experimental requirements.  
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Isolation and analysis of RNA 
Total RNA from whole tissue of LV lower transversal mid-section was isolated by the guanidine 
thiocyanate-CsCl method (Rysä et al. 2010). Extraction of RNA from NRVM and NRVF was 
performed using the E.Z.N.A.® Total RNA Kit I (Omega Bio-Tek Inc. Norcross, GA, USA) according 
to the manufacturer’s instructions. The RNA derived from LV tissue or neonatal cells was used as 
template to synthesize cDNA using Transcriptor First-Strand cDNA Synthesis Kit (Roche 
Diagnostics, Mannheim, Germany) according to the manufacturer’s instructions. Real-time 
quantitative polymerase chain reaction (RT-qPCR) with TaqMan chemistry (Life Technologies) was 
used for RNA expression level analysis on an ABI 7300 sequence detection system (Applied 
Biosystems, Life Technologies) as previously described (Tenhunen et al. 2006b). The primers and 
fluorogenic probes utilized for RT-qPCR were all purchased for Sigma Aldrich and are listed in the 
Electronic Supplementary Material, Table 2. 
 
Protein extraction and western blotting 
Total and nuclear protein extraction for Western blot analyses were performed as previously 
described (Tenhunen et al. 2006a). Protein levels were detected using fluorescence with Odyssey 
Fc imaging system (LI-COR Biosciences, Lincoln, NE, USA). The bands were quantified with Image 
Studio software (LI-COR). Table 1 in the Electronic Supplementary Material contains the details of 
all the antibodies utilized. 
 
Luciferase reporter assay 
COS-1 cells were maintained in DMEM containing 10% FBS. The cells were transfected with pGL-
III Basic vector coding for beetle luciferase containing 1.8-kb fragment of MMP-9 promoter (pGL-III 
- pMMP-9 - Luc) (Eberhardt et al. 2002) and different concentrations of pCGN-PEX1 or pCGN empty 
control plasmid. Transfections were carried out using FUGENE-6 reagent (Promega Corporation, 
Madison, WI, USA) according to the manufacturer's instructions. The transfections were performed 
as triplicates and repeated at least three times to ensure reproducibility of the results. Transfection 
with pCMV coding for β-galactosidase was used to control for transfection efficiencies. Luciferase 
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and β-galactosidase activities were measured with Luciferase Assay System kit (Promega 
Corporation) and Luminescent Beta-galactosidase Detection Kit II (Clontech Laboratories, Inc., 
Mountain View, CA, USA) using an automated chemiluminescence detector (Varioskan Flash, 
Thermo Fisher Scientific Oy, Vantaa, Finland) 
 
Data analysis and statistics 
For statistical analysis, data was first tested for normality by using the Shapiro-Wilk test. For normally 
distributed variables, pairwise comparisons between two groups were made by unpaired two-tailed 
Student’s t-test. For data that was not normally distributed, statistical analysis was performed by 
using non-parametric Mann–Whitney U-test. Probability values below 0.05 were considered 
significant. Results are reported as mean±standard deviation (SD). Statistical analyses were 
performed with SPSS software (SPSS Inc., Chicago, IL, USA).  
 
Results 
Augmentation and silencing of PEX1 expression by intramyocardial adenoviral gene transfer 
in vivo  
To investigate the potential role of PEX1 in cardiac remodeling, rats were subjected to in vivo 
intramyocardial gene transfer (Tenhunen et al. 2006a; Tenhunen et al. 2006b; Rysä et al. 2010) to 
locally modulate the LV levels of PEX1. Different doses of Ad5-HA-PEX1 and Ad5-AsPEX1 
adenoviral constructs were first tested to ensure up-regulation and down-regulation of LV PEX1 
expression, respectively. As shown in Fig. 1a, PEX1 mRNA levels markedly increased at day 3 after 
the gene transfer in the Ad5-HA-PEX1-injected group when compared to LacZ-injected animals 
(21.4-fold, P<0.005), remained elevated at 1 week (3.6-fold, P<0.01), and returned to basal levels 2 
weeks post-intervention. On the other hand, silencing of PEX1 expression by adenoviral delivery of 
AsPEX1 construct resulted in significant down-regulation of PEX1 mRNA levels at 2 weeks after 
gene transfer (Fig. 1a). The presence of PEX1 in LV was confirmed by immunostaining the heart 
sections using anti-PEX1 antibody (Fig. 1b-d’’). The strongest signal was observed at day 3 in Ad5-
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HA-PEX1-treated hearts (Fig. 1c), mostly localized around the areas of injection, and being almost 
absent from LacZ- (Fig. 1b-b’’) and AsPEX1-injected animals (Fig. 1d-d’’). To characterize further 
the efficiency and localization of the PEX1 gene delivery, consecutive histological slices from PEX1 
overexpressing hearts at 3 days were used for double immunofluorescent detections of PEX1 with 
the cell-type specific markers sarcomeric α-actinin for myocytes and P4H for fibroblasts. PEX1 co-
localized with α-actinin and P4H, demonstrating that PEX1 overexpression occurred in both cell 
types, approximately 60 % of PEX1-positive were myocytes and 25 % were fibroblasts (Fig. 2).  
 
PEX1 induces fibrotic process in the adult heart 
Intramyocardial delivery of PEX1 adenoviral construct in the normal rat heart triggered significant 
augmentation of interstitial fibrosis at 2 weeks, as measured by Masson’s trichrome (Fig. 3a, a’, b, 
b’, c, c’, d) and Picrosirius red stainings (Fig. 3a’’,b’’,c’’). We also assessed changes in the expression 
of genes involved in the fibrotic and remodeling processes by RTqPCR from LV tissue extracts. 
Collagens Iα1 and IIIα1 are major components of the ECM, whose expression was significantly 
increased (P<0.01) at day 3 in response to PEX1 overexpression (Fig. 3e, f). Interleukin-6 (IL-6), an 
early mediator of the inflammatory response to stress injury, was also significantly up-regulated at 3 
days (Fig. 3g). Interestingly, MMP-9 mRNA levels rose 8.9-fold at 3 days (P<0.005) and 
progressively returned to baseline levels at 1 and 2 weeks in response to PEX1 overexpresssion 
(Fig. 3h). A more moderated and sustained effect on MMP-2 was observed; MMP-2 mRNA levels 
were 2-fold higher in PEX1 overexpressing hearts than the control group at 3 days and 1 week (Fig. 
3i; P<0.01 and P<0.05, respectively). Matrix deposition of FN-1 is induced by TGFβ1 and promoted 
by connective tissue growth factor (CTGF) (Leask and Abraham 2004), which is also a mediator of 
TGFβ1 actions (Chen et al. 2000; Abreu et al. 2002; Garrett et al. 2004; Leask and Abraham 2004). 
While FN-1 mRNA levels remained substantially elevated at 3 days and 1 week after gene transfer 
(Fig. 3j), the expression of TGFβ1 and CTGF were increased at 3 days and returned to basal levels 
after 1 week (Fig. 3k, l). Similarly, α-SMA (also known as Acta2), a well-established marker for 
cardiac fibroblast to myofibroblasts transdifferentiation, followed the same expression pattern as pro-
fibrotic genes being significantly up-regulated by PEX1 overexpression at 3 days (Fig. 3m). 
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Furthermore, α-SMA was localized with PEX1 (Electronic Supplementary Material, Fig. S1). On the 
other hand, silencing of PEX1 expression by AsPEX1 adenoviral construct at 2 weeks had an 
opposite effect on the transcriptional regulation by causing significant reduction of mRNA levels of 
genes typically activated during the ECM remodeling and fibrotic process (Fig. 3e-m). 
 
Cell-specific actions of PEX1 on fibrosis-related gene expression 
Since PEX1 co-localized with α-actinin and P4H in the adult heart, we next studied whether PEX1 
has differential effects on gene expression in fibroblasts and myocytes. Gain- and loss-of-function 
studies were conducted in vitro using NRVM and NRVF harvested from 2-4 days old rats and were 
transfected with Ad5-HA-PEX1 or PEX1-siRNA for overexpression or silencing studies, respectively. 
As shown in Fig. 4, PEX1 overexpression at 24 and 48 hours markedly increased MMP-2 and MMP-
9 mRNA levels in NRVFs, while no significant changes were observed in NRVMs. Similarly, the pro-
inflammatory cytokine IL-6 mRNA levels were significantly increased in NRVF. Interestingly, α-SMA 
and CTGF mRNA levels were down-regulated in NRVF, but not in NRVM, whereas changes in 
mRNA levels of FN-1 (Fig. 4), collagens and other profibrotic markers (data not shown) explored 
were not statistically significant.  
Silencing experiments were conducted for 48 (Fig. 5a-d) and 72 hours (Fig. 5e-h) with PEX1-
siRNA in NRVFs. PEX1 mRNA levels were reduced 31% at 48h (P<0.05) and 37% at 72h (P<0.005) 
compared to control (Fig. 5a, e). Significant changes in gene expression were specifically observed 
after 72 hours (Fig. 5b): IL-6 and FN-1 mRNA levels were diminished (29% and 17%, P<0.01; Fig. 
5f, h), and a similar decreasing trend (34%, not significant) was noted for MMP-9 (Fig. 5g).  
 
 
 
PEX1 activates the MMP-9 promoter  
Both in vivo and in vitro results suggest that PEX1 may directly regulate pro-fibrotic genes, including 
MMP-9. As shown in Fig. 6, also protein levels increased subsequent to PEX1 overexpression in 
vivo already at 3 days. The promoter region of MMP-9 has a PEX1 binding region (PERE), upstream 
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of the coding region (Fig. 7a) which is conserved in the promoters of human, mouse, and rat 
genomes. Therefore, we used a luciferase reporter approach to explore whether PEX1 could directly 
bind the promoter region of MMP-9 and regulate MMP-9 transcription. COS-1 cells were transfected 
with pCMV-PEX1 and pGL-III-pMMP9-Luc plasmids. In reporter gene studies, PEX1 increased 
MMP-9 promoter activity in a dose-dependent manner (Fig. 7b), demonstrating that PEX1 activates 
the promoter of MMP-9. 
 
PEX1 overexpression leads to reactivation of the fetal gene program 
Next, we studied the effects of gain- and loss-of PEX1 function on transcriptional regulation of fetal 
gene program in vivo. Gene expression analysis by RT-qPCR revealed activation of genes 
associated with the hypertrophic process in response to PEX1 overexpression, while the antisense 
construct had opposing effects. Significant increases of the mRNA levels of A-type natriuretic peptide 
(ANP), BNP and skeletal α-actin (Acta1) (Electronic Supplementary Material, Fig. S2a, b, g) were 
detected at day 3 of PEX1 overexpression, while PEX1 silencing significantly decreased BNP, Acta1, 
and cardiac α-actin (Actc1) mRNA levels (Electronic Supplementary Material, Fig. S2). In addition, 
significantly reduced α-MHC to β-MHC and Actc1 to Acta1 ratios were detected in PEX1 injected 
hearts when compared to the LacZ control group (Electronic Supplementary Material, Fig. S2e, h), 
indicating the transcriptional switch from adult to fetal isoforms of contractile genes. 
 
Effects of gain- and loss-of PEX1 on cardiac function and structure in adult heart 
The cardiac function and structure were evaluated by echocardiography in vivo. Overall, the results 
of echocardiography analysis show that augmentation or silencing of PEX1 expression had no major 
effect on LV structure and function in normal rat hearts during the 2 weeks follow-up period. Yet, in 
agreement with the decreased fibrotic process, AsPEX1 adenoviral delivery slightly but significantly 
increased LVEF and LVFS at 2 weeks (Table1). As the LV remodeling process is characterized by 
the increased presence of apoptotic and stem cells, increased cell proliferation, and hypertrophied 
myocytes, we also analyzed these parameters by immunological detection in LV histological cross 
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sections. As shown in Electronic Supplementary Material, Fig. S3, no significant changes in number 
of apoptotic cells, Ki-67+ cells, c-kit+ cells or myocyte size were observed. 
 
Effects of PEX1 overexpression and silencing in Ang II-induced hypertension and post-
infarction in adult heart 
Finally, the effects of PEX1 and AsPEX1 gene transfers on myocardial fibrosis were examined post-
MI and in Ang II-induced hypertension in adult rats by quantification of expression of fibrotic genes 
levels and staining of histological sections by Masson’s trichrome. Adenovirus-mediated PEX1 gene 
delivery increased PEX1 mRNA levels in both experimental models at 1 week while the down-
regulation of PEX gene expression by Ad5-AsPEX1 local injection was not statistically significant 
(Fig. 8a, b). There was a tendency towards augmented fibrosis by overexpressing PEX1, but this 
change was not statistically significant (Fig. 8g, h). In Ang II-induced hypertension, PEX1 
overexpression promoted the expression of the fibrotic genes, including collagen Iα1 and IIIα1 
isoforms, FN-1 and MMP-2. Although TGFβ1 levels were down-regulated at 1 week by the antisense 
construct, surprisingly, the expression of MF marker α-SMA was up-regulated by PEX1 
overexpression in Ang II-induced hypertension model (Fig. 8a). PEX1 adenovirus-mediated 
overexpression post-infarction caused significant increase of IL-6 expression and down-regulation 
of α-SMA expression at 1 week. Gene expression analysis of the animals subjected to LAD in 
combination with local adenoviral injection of AsPEX1 revealed significant down-regulation of CTGF, 
FN-1 and TGFβ1 at 1 week (Fig. 8b) and of TGFβ1 and MMP-2 at 2 weeks (data not shown). 
 
Discussion 
The heart responds to biomechanical stress and neurohumoral stimuli by activating signaling 
pathways that induce myocardial remodeling. Cardiac fibroblasts play an essential role in the 
remodeling response, as they are not only important modulators of ECM homeostasis but also of the 
inflammatory response, acting as source of matricellular components, cytokines and growth factors 
(Lindner et al. 2014). ECM production and crosslinking are keys to provide a support structure during 
the healing process. However, loss of homeostatic balance of ECM remodeling and excessive 
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accumulation of structural proteins, such as collagens, leads to stiffer myocardial tissue, loss of 
contractility and eventually heart failure. PEX1 is a transcriptional regulator of the hypertrophic 
signaling, which is activated by α1-adrenergic stimulus, and co-operates with GATA4 to induce 
cardiac hypertrophic response (Debrus et al. 2005; Komati et al. 2011). The current study shows 
that PEX1, in addition to regulating cardiomyocyte hypertrophy, influences ECM turnover and cardiac 
fibrosis in the adult heart. 
The main finding of this study is that PEX1 regulates key pro-fibrotic genes in the heart. In our 
study, cardiac fibrosis was increased by local PEX1 injection into the LV wall of normal adult rat 
hearts. Consistent with the increased fibrosis, expression of pro-fibrotic factors was activated 
subsequently to overexpression of PEX1. Accordingly, silencing of PEX1 repressed the expression 
of these pro-fibrotic genes. Particularly, we observed significant changes in the expression of 
cytokines, matrix metalloproteases and matricellular proteins, which all play a role in the 
inflammatory and fibrotic responses to pathological stress. In addition, overexpression of PEX1 in 
LV of adult rats up-regulated cardiac hypertrophy associated genes, noted by activation of ANP and 
BNP gene expression, and reactivation of the fetal gene program, which all are fundamental features 
of hypertrophic response of cardiomyocytes (Chien 1999; Oka et al. 2007; Braunwald 2013). These 
latter results are in line with the previous study, where PEX1 overexpression in cardiomyocytes was 
sufficient to induce myocardial hypertrophy and reactivation of the fetal gene program (Komati et al. 
2011). However, Komati and colleagues (Komati et al. 2011) did not find evidence of ECM 
remodeling by overexpressing PEX1 in cardiac myocytes. These differences observed in vivo 
experiments are most likely due to the different experimental models used. In the study by Komati 
et al. (Komati et al. 2011), a conditional transgenic mouse line that overexpresses PEX1 specifically 
and intensively in cardiomyocytes upon tamoxifen administration was used, whereas in our study 
PEX1 overexpression was more transient and PEX1 co-localized with α-actinin and P4H, indicating 
that PEX1 overexpression occurred in both myocytes and fibroblasts.  
TGFβ1 is a major contributor of the profibrotic response, and also several cytokines such as 
IL-6 play a relevant role in the early response to myocardial stress, and the development of fibrosis. 
In the present study, TGFβ1 expression in adult rat heart was induced by PEX1 overexpression and 
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inhibited upon silencing, whereas IL-6 was up-regulated by PEX1 consistently in all our experimental 
models. Once activated, TGFβ1 can elicit fibroblast to MF transdifferentiation by inducing the 
expression of collagens (specially I and III isoforms), FN-1, and α-SMA (Yu and Stamenkovic 2000; 
Dobaczewski et al. 2010). Of note, in view of the role of α-SMA in transdifferentiation, it localized 
with PEX1 in LV 3 days after gene delivery. Furthermore, TGFβ promotes synthesis of matricellular 
and ECM proteins, such as fibronectin, CTGF, and IL-6, which in turn regulate the capability of TGFβ 
to induce MF transdifferentiation (Serini et al. 1998; Chen et al. 2000; Ma et al. 2012). Independently 
of the etiology of the stimuli, MF transdifferentiation is a hallmark of both reactive and reparative 
fibrosis (Cleutjens et al. 1995; Sun 2000). Moreover, IL-6 contributes to the inflammatory response 
in heart (Gullestad et al. 2012; Turner 2015) and several studies provide evidence of IL-6 as a 
mediator in cardiac fibrosis (Sano et al. 2000; Meléndez et al. 2010; Ma et al. 2012). Meléndez and 
colleagues showed that IL-6 administration could induce fibrosis, concentric LV hypertrophy and 
diastolic dysfunction, consistent with the response occurring in hypertensive hearts (Meléndez et al. 
2010). Our gene expression analysis revealed that mRNA levels of pro-fibrotic genes collagens Iα1 
and IIIα1, FN-1, CTGF, and α-SMA were increased by PEX1 overexpression in normal hearts in vivo 
similarly to TGFβ1. Altogether this is in agreement with the activation of TGFβ1 fibrotic pathway 
subsequent to PEX1 overexpression, shown by increased presence downstream targets linked to 
MF transdifferentiation and upstream modulators of TGFβ1. Overall, these findings provide evidence 
for the fibroblast activation as the main factor responsible for the cardiac fibrosis subsequently to 
PEX1 overexpression. Yet, despite that PEX1 did not increase the number of apoptotic nuclei in our 
in vivo experimental model, we cannot exclude the possibility of other cell death processes, such as 
necrosis, contributed to the observed increase in cardiac fibrosis. It is also noteworthy that PEX1 
gain- and loss-of-function experiments in vitro in rat neonatal cardiac fibroblasts and myocytes 
revealed that pro-fibrotic gene expression was affected by PEX1 predominantly in fibroblasts. 
The latent form of TGFβ1 can be produced by a number of cell types including the main 
resident cells of the heart, fibroblasts and myocytes; yet inflammatory cells, such as neutrophils and 
macrophages, which can infiltrate the myocardium, constitute another important source. Proteases 
MMP-2 and MMP-9 have been shown to release the ECM-bound latent TGFβ1(Yu and Stamenkovic 
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2000; Bujak and Frangogiannis 2007; Dayer and Stamenkovic 2015). Interestingly, MMP-2 and 
MMP-9 were markedly up-regulated in vivo and in cultured NRVF. More importantly, PEX1 has 
stimulatory effect on MMP-9 protein levels in vivo and MMP-9 promoter activity, as shown by 
luciferase reporter gene experiments. Therefore, it is tempting to speculate that PEX1 possibly 
modulates ECM homeostasis by increasing the amount of MMP-9 produced by the cells, leading to 
increasing amounts of active MMP-9, which then could release and activate interstitial TGFβ1 latent 
form. MMP-9 is an active player in the inflammatory-fibrotic response secreted by a wide number of 
cell types, from endothelial to neutrophils, macrophages and fibroblasts (Yabluchanskiy et al. 2013; 
Ma et al. 2014).  Thus, the increased MMP-9 expression in vivo may be induced in inflammatory 
cells as well, possibly caused by PEX1 promotion of the inflammatory response, as indicated by 
increased expression of inflammatory markers in response to PEX1 overexpression. MMP-9 is 
strongly present in cardiovascular diseases and associated with negative outcome, such as 
increased aortic stiffness and adverse LVH in hypertension or post-MI LV dilatation, and several 
studies have shown the benefits of inhibiting or silencing MMP-9 (Romanic et al. 2001; Ikonomidis 
et al. 2005; Takai et al. 2007; Krishnamurthy et al. 2009).  
Activation of α1-adrenergic receptors in animal models of hypertension in vivo and in cultured 
cardiomyocytes up-regulates PEX1 expression (Debrus et al. 2005; Komati et al. 2011). Therefore, 
we explored the effects of PEX1 modulation by local adenoviral gene transfer in Ang II-mediated 
hypertension and post-infarction. Even though PEX1 mRNA was significantly overexpressed, we did 
not detect statistically significant changes in the fibrotic tissue content. Moreover, PEX1 effect on α-
SMA expression was opposite to the observations in normal hearts. In line with the findings in 
pathological models, a strong down-regulation of α-SMA and CTGF mRNAs in response to PEX1 
overexpression was detected also in NRVF primary cultures. One possible explanation to weak 
induction of fibrosis-associated genes in diseased hearts is that PEX1 levels are elevated in Ang II-
induced hypertension (Jurado Acosta et al., unpublished data) or post-infarction. On the other hand, 
TGFβ1 expression was down-regulated by PEX1 silencing in the models of hypertension and 
myocardial infarction, indicating that PEX1 may contribute to up-regulation of TGFβ1 expression in 
response to stress stimuli in the heart. TGFβ1-induced MF contractile capabilities require of CTGF 
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(Garrett et al. 2004), yet incorporation of α-SMA into the fibroblast cytoskeleton confers contractile 
properties, the most defining characteristic of MF (Ma et al. 2014). However, although PEX1 affects 
the fibrotic process in heart, the cardiac function was preserved in our experimental models, similarly 
to previous studies where transgenic mice with inducible PEX1 developed LVH without effect on the 
heart function (Komati et al. 2011). In a pathological environment, other neurohumoral factors, 
physical stimuli and damage-associated molecules are present which may alter or complement 
PEX1 actions observed in a normal heart. A limitation of this study is that the in vitro models are 
isolated cells in a much simpler context than the ones found in vivo, lacking ECM, paracrine signaling 
and communication between different cell types. In addition, the interpretation of the findings in 
models of angiotensin-induced cardiac remodeling and myocardial infarction is challenging, since 
the changes in endogenous levels of PEX1 following cardiac stress injuries complicate interpretation 
of any effects of the overexpression and knockdown strategies. Nevertheless, our study clearly 
showed that PEX1 promotes the expression of MMPs in NRVF, even though the effects of the 
proteolytic activity observed in vivo may be lost without ECM, since there is no interstitial TGFβ that 
cannot be activated to trigger the fibrotic signaling. The precise mechanisms for the distinct cardiac 
actions of PEX1 remain to be established, but may be due to diverse pathophysiological processes 
occurring in MI and hypertension-induced heart disease (Jessup and Brozena 2003; McMurray and 
Pfeffer 2005). Previously we have reported that several gene transfers in these animal models lead 
to different effects on cardiac structure and function depending on the distinct signaling networks 
activated in each experimental model (Tenhunen et al. 2006a; Tenhunen et al. 2006b; Moilanen et 
al. 2011). Overall, in the present study we could study structural and functional changes during the 
early remodeling process, because adenoviral gene delivery results in transient increase in PEX1 
expression. Therefore, to study the longer-term effects on extracellular matrix turnover, detailed 
experiments in other models are needed. 
In conclusion, our findings provide a new insight into the regulation of ECM remodeling and 
the fibrotic process in the heart. The results indicate that PEX1 induces ECM remodeling and a 
beneficial type of fibrosis, which imitates the protective fibrotic response occurring in stressed 
myocardium. Interestingly, very recently adult fibroblasts reprogramming have been used to 
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generate proliferative induced cardiac progenitor cells which could be directed into different 
cardiovascular cell lineages (Lalit et al. 2016), highlighting the ability of fibroblasts to protect and 
regenerate the heart. Our results further indicate that PEX1 stimulates MMP-9 promoter activity, 
which might trigger the pro-fibrotic response directed by PEX1. The schematic diagram in Fig.9 
illustrates a possible mechanism of action according to the findings of this study combined with 
previous findings. We suggest that through promoting MMP-9 expression, PEX1 induces the 
activation of interstitial TGFβ1, which in turn activates the expression of ECM components by 
inducing the transdifferentiation into a synthetic and contractile cell type, myofibroblasts. In addition 
to MMPs effects on ECM turnover, processing of cytokines, chemokines and growth factors, there 
are other ways by which MMPs can influence inflammatory and fibrotic pathways. In this study, PEX1 
overexpression in non-myocyte resident cells, such as fibroblasts, was predominantly responsible 
for the fibrosis-associated changes observed.  
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Figure Legends 
Fig. 1 Cardiac specific augmentation and silencing of PEX1 expression by adenoviral gene 
delivery into the LV in rats in vivo. a PEX1 mRNA levels were measured by RT-qPCR from LV 
extracts and normalized to Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) housekeeping 
gene. The results are expressed as mean±SD (N=5 to 10 animals/group). * P<0.05, ** P<0.01, 
***P<0.005 versus LacZ control (Student’s t-test or Mann Whitney U-test). b-d’’ Efficiency of gene 
transfer was confirmed by immunohistochemical staining against PEX1. Representative images 
from LacZ (b-b’’), HA-PEX1 (c-c’’) and AsPEX1 (d-d’’) adenovirus-treated hearts are shown. 
Hearts treated with PEX1 show strongest signal. The scale bar is 100 µm 
Fig. 2 PEX1 adenoviral gene transfer in rats in vivo increases PEX1 levels in cardiac myocytes 
and fibroblasts. Cell specificity of PEX1 protein expression was evaluated by immunofluorescent 
co-staining with prolyl-4-hydroxylase (P4H, a fibroblast marker) and sarcomeric α-actinin (a 
myocyte marker). Representative images are shown from LacZ (a-b’’’), PEX1 (c-d’’’) and AsPEX1 
(e-f’’’) treated hearts at day 3 after injection. Consecutive slices were used for α-actinin and P4H 
double stainings with PEX1, and images depict the same LV area for α-actinin and P4H. White 
arrow heads indicate co-localization of the specific cell marker and PEX1 in the merged images 
(a’’’, b’’’, c’’’, d’’’, e’’’, f’’’). The scale bar is 50 µm 
Fig. 3 PEX1 overexpression in normal rat heart increases fibrosis and expression of genes 
involved in the fibrotic process. a-c’’ Representative images LV histological sections stained with 
Masson’s trichrome (a, a’, b, b’, c, c’) and picrosirius red under polarized light (a’’,b’’,c’’). d 
Masson’s trichrome fibrotic tissue stain quantification from 5 hotspots in the LV. The results are 
expressed as mean±SD. *P<0.05 versus LacZ control (N=6 to 9 animals/group, Student’s t-test). e-
m Fibrotic gene program was activated in normal rat heart after PEX1 overexpression when 
compared to LacZ control, as evident by increased mRNA levels of collagens (e, f), cytokine IL-6 
(g), MMP-9 and MMP-2  (h, i), FN-1 (j), TGFβ1 (k), CTGF (l), and α-SMA (m) at day 3 after 
injection. mRNA levels were measured by RT-qPCR from LV extracts and normalized to GAPDH 
housekeeping gene. The results are expressed as mean±SD.* P<0.05, ** P<0.01, ***P<0.005 
versus LacZ control (N= 6 to 9 animals/group, Student’s t-test or Mann Whitney U-test) 
Fig. 4 Differential effects of PEX1 adenoviral overexpression in NRVF and NRVM in vitro. The 
mRNA levels were quantified by RTqPCR 24 hours (a-g) or 48 hours (h-n) after adenovirus gene 
transfer and normalized to 18S housekeeping gene. The results are expressed as mean±SD. * 
P<0.05, ** P<0.01, ***P<0.005 versus LacZ control (N=5 to 7 (a-g) and 2 to 3 (h-n), Student’s t-test 
or Mann Whitney U-test) 
Fig. 5 Effects of PEX1 silencing in NRVF. Primary cells were transfected with PEX1-siRNA or 
AllStar-siRNA for 48 hours (a-d) or 72 hours (e-h). The mRNA levels of PEX1 (a, e), IL-6 (b, f), 
MMP-9 (c, g) and FN-1 (d, h) were quantified by RT-qPCR. The results are expressed as 
mean±SD * P<0.05, ** P<0.01, ***P<0.005 versus AllStar-siRNA negative control (N=5 to 6, 
Student’s t-test or Mann Whitney U-test) 
Fig. 6 MMP-9 protein levels were increased 3 days after PEX1 adenoviral gene transfer in normal 
heart.  Quantification of MMP-9 nuclear and total protein levels. The MMP-9 (105kDa) values were 
normalized to LaminB (50kDa, nuclear protein fraction) or GAPDH (36kDa, total protein fraction), 
representative Western blots are shown. The results are expressed as mean±SD * P<0.05 relative 
to LacZ adenovirus control (N=3-4, Student’s t-test) 
Fig. 7 PEX1 activates the MMP-9 promoter. a Sequence of the upstream 1.3 kb of the rat MMP-9 
gene promoter. Putative binding region for PEX1, the phenylephrine response element binding site 
(PERE), is underlined. The schematic representation of the upstream region is included in the 
figure. b Luciferase activity of the MMP-9 promoter construct is increased in the presence of PEX1 
expressing plasmid in a dose dependent manner. The results are expressed as mean±SD * 
P<0.05, ** P<0.01, ***P<0.005 versus lower pCGN-PEX1 concentration; ^ P<0.05, ^^ P<0.01, 
^^^P<0.005 versus pCGN control (N=3, Student’s t-test) 
Fig. 8 Effects of adenovirus mediated PEX1 gain-and loss-of-function in Ang II-induced 
hypertension and post-infarction in rats. Changes in fibrosis associated gene-expressions at 1 
week were quantified by RT-qPCR and normalized to GAPDH (a, b). Representative images of 
Masson’s trichrome staining from LV histological sections from 1 week Ang II infused (c-d’’) and MI 
animals (e-f’’). The scale bar is 50 µm. Fibrosis quantifications were made from 5 hotspots from 
the LV of Ang II-induced hypertension (g) and post-infarction (h) rats. The results are expressed as 
mean±SD (N=6 to 9 animals/group). * P<0.05, ** P<0.01, ***P<0.005 versus LacZ control 
(Student’s t-test or Mann Whitney U-test) 
Fig. 9 A schematic presentation of the effects of PEX1 in the heart 
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Supplementary Table 1. Antibodies employed. 
Antigen Product # Manufacturer Detection Application 
PEX1, Zfp260 - Debrus S, et al. MCB (2005) Primary IHC & IHF 
Prolyl-4-hydroxilase MAB2073 Millipore Primary IHF 
Sarcomeric α-actinin  A7811 Sigma-Aldrich Primary IHF 
α-SMA AB5694 Abcam Primary IHF 
WGA-FITC W11261 Thermofisher Primary IHC 
Ki-67 M7248 Millipore Primary IHC 
c-kit sc-168 Santa Cruz Primary IHC 
vWF AB7356 Abcam Primary IHC 
MMP-9 AB76003 Abcam Primary WB 
Lamin B sc-6216 Santa Cruz Primary WB 
GAPDH MAB374 Millipore Primary WB 
AlexaFluor 568 anti-rabbit A11036 Invitrogen (Eugene, Oregon, US) Secondary IHF 
Biotinylated anti-mouse IgG BA-2001 Vector Laboratories, Inc. (Burlingame, CA) Secondary IHF 
Alexa Fluor 680 anti-mouse A21058 Invitrogen Secondary WB 
Alexa Fluor 680 anti-rabbit A21076 Invitrogen Secondary WB 
IrDye 700 anti-goat 605-730-125 Rockland Secondary WB 
PEX1= phenylephrine-induced complex-1; α-SMA= alpha-smooth muscle actin; WGA-FITC= wheat germ 
agglutinin/5’-fluorescein isothiocyanate; vWF= von Willebreand factor; MMP-9= metalloproteinase 9; 
GAPDH=glyceraldehyde 3-phosphate dehydrogenase; IHC= Immunohistochemistry; IHF= 
Immunohistofluorescence; WB= Western blot 
 
 
 
  
Supplementary Table 2. Forward and reverse primer and fluorogenic probe sequences used for 
real time quantitative RT-PCR analysis. 
Gene Primer Fluorogenic probe 
ANP (F) GAAAAGCAAACTGAGGGCTCTG TCGCTGGCCCTCGGAGCCT 
 
(R) CCTACCCCCGAAGCAGCT 
 
α-SMA (F) TCCTGACCCTGAAGTATCCGATA AACACGGCATCATCACCAACTGGGA 
 
(R) GGTGCCAGATCTTTTCCATGTC 
 
α-MHC (F) GCAGAAAATGCACGATGAGGA TAACCTGTCCAGCAGAAAGAGCCTCGC 
 
(R) CATTCATATTTATTGTGGGATAGCAAC 
 
BNP (F) TGGGCAGAAGATAGACCGGA CGGCGCAGTCAGTCGCTTGG 
 
(R) ACAACCTCAGCCCGTCACAG 
 
β-MHC (F) GCTACCCAACCCTAAGGATGC TGTGAAGCCCTGAGACCTGGAGCC 
 
(R) TCTGCCTAAGGTGCTGTTTCAA 
 
Acta1 (F) TCCTCCGCCGTTGGCT CATCGCCGCCACTGCAGCC 
 
(R) AATCTATGTACACGTCAAAAACAGGC 
 
Actc1 (F) GGGCCCTCCATTGTCCA CGCAAGTGCTTCTGAGGCGGCTAC 
 
(R) GCACAATACTGTCGTCCTGAGTG 
 
Col Iα1 (F) CCCCTTGGTCTTGGAGGAA 
CTTTGCTTCCCAGATGTCCTATGGCTAT
GATG 
 
(R) GCACGGAAACTCCAGCTGAT 
 
Col IIIα1 (F) AGCTGGCCTTCCTCAGACTTC TTCCAGCCGGGCCTCCCAG 
 
(R) GCTGTTTTTGCAGTGGTATGTAATG 
 
CTGF (F) CGCCAACCGCAAGATTG CACTGCCAAAGATGGTGCACCCTG 
 
(R) CACGGACCCACCGAAGAC 
 
FN-1 (F) GCGAGGCAGGATCAGCTG ACCATTGCAAATCGCTGCCATGAA 
 
(R) CCAATCTTGTAGGACTGACCCC 
 
GAPDH (F) GGTCATCATCTCCGCCCC CCGCTGATGCCCCCATGTTTG 
 
(R) TTCTCGTGGTTCACACCCATC 
 
IL-6 (F) CAGAATTGCCATTGCACAACTCTTTTCTCA TGCATCATCGCTGTTCATACAA 
 
(R) ATATGTTCTCAGGGAGATCTTGGAA 
 
MMP-2 (F) CATGAAGCCTTGTTTACCATGG TGGCAATGCTGATGGACAGCCC 
 
(R) TGGAAGCGGAACGGAAACT 
 
MMP-9 (F) CCGCCAACTATGACCAGGATAA TGTATGGCTTCTGTCCTACTCGAGCCGA 
 
(R) AGTTGCCCCCAGTTACAGTGA 
 
PEX1 (F) TGAAGAGAGACCCAGTGAGTC AACTCCCGTCCCCATGACAACCATC 
 (R) TTCCCGGCGTTTCTCTGAT  
TGFβ1 (F) CATCGACATGGAGCTGGTGA ACGGAAGCGCATCGAAGCCATC 
 
(R) TTGGACAGGATCTGGCCAC 
 
18S (F) TGGTTGCAAAGCTGAAACTTAAAG CCTGGTGGTGCCCTTCCGTCA 
  (R) AGTCAAATTAAGCCGCAGGC   
ANP and BNP = A-type and B-type natriuretic peptide; α-SMA= alpha-smooth muscle actin; MHC= myosin 
heavy chain; Acta1= skeletal alpha-actin; Actc1= cardiac alpha-actin; Col= collagen; CTGF= connective 
tissue growth factor, FN-1= fibronectin-1, GAPDH=glyceraldehyde 3-phosphate dehydrogenase, IL-6= 
interleukin-6, MMP= metalloproteinase; PEX1=phenylephrine-induced complex-1; TGFβ1= transforming 
growth factor β1, F= forward; R=reverse. 
 
 
  
Supplementary Figure Legends 
Fig. S1 α-SMA co-localizes with PEX1 in LV. Localization of PEX1 protein expression in 
myofibroblasts was evaluated by immunofluorescent co-staining with anti-α-SMA antibody (a 
myofibroblast marker). Representative images are shown from LV of PEX1 treated hearts at day 3 
after injection. White arrow heads indicate co-localization of the specific cell marker and PEX1 in 
the merged images (bottom right). The scale bar is 50 µm 
Fig. S2 PEX1 overexpression leads to reactivation of the fetal gene program in adult rat heart. The 
mRNA levels of ANP(a), BNP(b), α-MHC(c), β-MHC(d), the ratio of α- to β- MHC isoforms(e), 
Actc1(f), Acta1(g), and  the ratio of Actc1 to Acta1(h) were quantified by RT-qPCR and normalized 
to GAPDH. The results are expressed as mean±SD (N= 5 to 10 animals/group). * P<0.05, ** 
P<0.01, ***P<0.005 versus LacZ control (Student’s t-test or Mann Whitney U-test) 
Fig. S3 Immunohistochemical evaluation of PEX1 gain- and loss-of-function revealed no significant 
changes in apoptosis, proliferation, number of stem cells or cell size. A) Representative images 
from 2 weeks normal rat heart histological sections are shown. The rate of apoptosis was 
assessed by TUNEL, immunohistochemical staining against Ki-67 was performed to study cellular 
proliferation, c-kit was used to stain stem cells, and to stain the cell extracellular membrane WGA 
was used. b-e Quantifications of TUNEL positive cells (b), dividing cells, indicated by Ki-67 marker 
(c), c-kit positive stem cells (d), and cross sectional area of myocytes using WGA (e) were 
performed by computerized methods (N= 6 to 9 animals/group, c-e N=2 for LacZ 1 week group). 
The results are expressed as mean±SD and compared to LacZ control group (Student’s t-test) 
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